RxDoctor Payments DataLook up a doctor →

Jonathan Riess

Hematology & Oncology · Sacramento, CANPI 1619132461

Payments from drug & device makers

$9,814,563in general payments, 2019–2025

Across 388 payments — averaging $25,295 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Clovis Oncology, Inc.$4.1M
  • AstraZeneca$1.6M
  • Merck$1.4M
  • Novartis$640K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$535K
  • Boehringer Ingelheim$492K
  • plus $1M from 34 others
$26,594in research payments, 2019–2025

Across 21 payments — averaging $1266.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$11K
  • Novartis$10K
  • Merck$4K
  • Pfizer$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,814,563 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$47,905
Medicare patients
169
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →